Saccharomyces boulardii in Maintenance Treatment of Crohn’s Disease

By M. Guslandi, G. Mezzi, M. Sorghi, P. Testoni. Digestive Diseases and Sciences, 2000

753 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Microorganisms with Claimed Probiotic Properties: An Overview of Recent Literature (2014, background): “boulardii has shown positive effects for patients with irritable bowel syndrome [59], preventing and treating relapses of inflammatory bowel disease and for treating moderate symptoms of ulcerative colitis [60,61].”
Probiotics and their fermented food products are beneficial for health (2006, background): “faecum containing therapeutic effect have multiple mechanisms of action that could disrupt the pathogenesis of HE and may make them superior to conventional treatment and lower portal pressure with a reduction in the risk of bleeding (Nanji et al. 1994; Cunningham-Rundles et al. 2000; De Santis et a”
Probiotics: an overview of beneficial effects (2002, background): “Inflammatory bowel disease (IBD) is clinically characterised by two overlapping phenotypes, Crohn's disease (CD) and ulcerative colitis (UC), which predominantly affect the colon (UC and CD) and/or the distal small intestine (CD).”